Cell-free DNA and neuromediators in detecting aggressive variant prostate cancer
BACKGROUND: Aggressive variant transformation in metastatic castration-resistant prostate cancer (mCRPC) represents an under-recognized phenomenon. There is an urgent need for non-invasive biomarkers to detect these variants and identify treatment alternatives. - METHODS: A prospective observational...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 10, 2018
|
| In: |
Oncology research and treatment
Year: 2018, Volume: 41, Issue: 10, Pages: 627-633 |
| ISSN: | 2296-5262 |
| DOI: | 10.1159/000490618 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1159/000490618
|
| Author Notes: | Jost von Hardenberg, Thomas S. Worst, Niklas Westhoff, Philipp Erben, Stefan Fuxius, Markus Müller, Christian Bolenz, Christel Weiss, Elmar Heinrich |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1662892004 | ||
| 003 | DE-627 | ||
| 005 | 20230426154249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190405s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000490618 |2 doi | |
| 035 | |a (DE-627)1662892004 | ||
| 035 | |a (DE-599)KXP1662892004 | ||
| 035 | |a (OCoLC)1341207939 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hardenberg, Jost von |d 1982- |e VerfasserIn |0 (DE-588)1020494328 |0 (DE-627)688149278 |0 (DE-576)360578241 |4 aut | |
| 245 | 1 | 0 | |a Cell-free DNA and neuromediators in detecting aggressive variant prostate cancer |c Jost von Hardenberg, Thomas S. Worst, Niklas Westhoff, Philipp Erben, Stefan Fuxius, Markus Müller, Christian Bolenz, Christel Weiss, Elmar Heinrich |
| 264 | 1 | |c September 10, 2018 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 05.04.2019 | ||
| 520 | |a BACKGROUND: Aggressive variant transformation in metastatic castration-resistant prostate cancer (mCRPC) represents an under-recognized phenomenon. There is an urgent need for non-invasive biomarkers to detect these variants and identify treatment alternatives. - METHODS: A prospective observational pilot study in mCRPC patients receiving treatment with cabazitaxel (CAB) was conducted. Neuromediators were sequentially evaluated and their impact on disease endpoints calculated. Targeted next-generation sequencing (NGS) of cell-free DNA (cfDNA) was also performed in a highly pretreated subset of patients. - RESULTS: 23 patients were included. Estimated effects indicate that neuron-specific enolase (NSE) levels at baseline may be correlated with overall survival (NSE unit 18.3 ng/ml: HR1.262 (95% confidence interval (CI) 0.985-1.616)) and that chromogranin A (CGA) may be correlated with progression-free survival (CGA unit 98.1 ng/ml: HR1.341 (95% CI 1.011-1.778)). cfDNA analysis revealed mutations annotated in prostate cancer (PCA) and small cell cancers (SCC). 1 patient showed elevated neuromediators along with annotated mutations in PCA and SCC, potentially indicating aggressive variant cancer. In 3 patients KIT mutations (e.g. pM541L, pV654A) known to be tissue-based biomarkers with level 1 evidence for the treatment with imatinib and sunitinib were found. - CONCLUSIONS: Sequential analysis of neuromediators and targeted NGS of cfDNA provide insight for the estimation of tumor heterogeneity under therapy with CAB. | ||
| 650 | 4 | |a Cabazitaxel | |
| 650 | 4 | |a CGA | |
| 650 | 4 | |a Liquid biopsy | |
| 650 | 4 | |a Neuroendocrine | |
| 650 | 4 | |a NSE | |
| 700 | 1 | |a Worst, Thomas |d 1985- |e VerfasserIn |0 (DE-588)1028335679 |0 (DE-627)73058500X |0 (DE-576)375827501 |4 aut | |
| 700 | 1 | |a Westhoff, Niklas Christian |d 1988- |e VerfasserIn |0 (DE-588)107322306X |0 (DE-627)828672628 |0 (DE-576)434741752 |4 aut | |
| 700 | 1 | |a Erben, Philipp |d 1973- |e VerfasserIn |0 (DE-588)128501014 |0 (DE-627)373920997 |0 (DE-576)297181661 |4 aut | |
| 700 | 1 | |a Bolenz, Christian |d 1976- |e VerfasserIn |0 (DE-588)133152707 |0 (DE-627)537509852 |0 (DE-576)29965754X |4 aut | |
| 700 | 1 | |a Weiß, Christel |d 1958- |e VerfasserIn |0 (DE-588)123287707 |0 (DE-627)082463417 |0 (DE-576)168356104 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology research and treatment |d Basel : Karger, 2014 |g 41(2018), 10, Seite 627-633 |h Online-Ressource |w (DE-627)776629611 |w (DE-600)2749752-5 |w (DE-576)400081660 |x 2296-5262 |7 nnas |a Cell-free DNA and neuromediators in detecting aggressive variant prostate cancer |
| 773 | 1 | 8 | |g volume:41 |g year:2018 |g number:10 |g pages:627-633 |g extent:7 |a Cell-free DNA and neuromediators in detecting aggressive variant prostate cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000490618 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190405 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 123287707 |a Weiß, Christel |m 123287707:Weiß, Christel |d 60000 |d 60200 |d 60250 |e 60000PW123287707 |e 60200PW123287707 |e 60250PW123287707 |k 0/60000/ |k 1/60000/60200/ |k 2/60000/60200/60250/ |p 8 | ||
| 998 | |g 133152707 |a Bolenz, Christian |m 133152707:Bolenz, Christian |d 60000 |d 63100 |e 60000PB133152707 |e 63100PB133152707 |k 0/60000/ |k 1/60000/63100/ |p 7 | ||
| 998 | |g 128501014 |a Erben, Philipp |m 128501014:Erben, Philipp |d 60000 |d 63100 |e 60000PE128501014 |e 63100PE128501014 |k 0/60000/ |k 1/60000/63100/ |p 4 | ||
| 998 | |g 107322306X |a Westhoff, Niklas Christian |m 107322306X:Westhoff, Niklas Christian |d 60000 |d 63100 |e 60000PW107322306X |e 63100PW107322306X |k 0/60000/ |k 1/60000/63100/ |p 3 | ||
| 998 | |g 1028335679 |a Worst, Thomas |m 1028335679:Worst, Thomas |d 60000 |d 63100 |e 60000PW1028335679 |e 63100PW1028335679 |k 0/60000/ |k 1/60000/63100/ |p 2 | ||
| 998 | |g 1020494328 |a Hardenberg, Jost von |m 1020494328:Hardenberg, Jost von |d 60000 |d 63100 |e 60000PH1020494328 |e 63100PH1020494328 |k 0/60000/ |k 1/60000/63100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1662892004 |e 3418317138 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"September 10, 2018"}],"note":["Gesehen am 05.04.2019"],"physDesc":[{"extent":"7 S."}],"person":[{"role":"aut","display":"Hardenberg, Jost von","given":"Jost von","family":"Hardenberg"},{"display":"Worst, Thomas","role":"aut","given":"Thomas","family":"Worst"},{"given":"Niklas Christian","family":"Westhoff","display":"Westhoff, Niklas Christian","role":"aut"},{"role":"aut","display":"Erben, Philipp","given":"Philipp","family":"Erben"},{"display":"Bolenz, Christian","role":"aut","given":"Christian","family":"Bolenz"},{"role":"aut","display":"Weiß, Christel","family":"Weiß","given":"Christel"}],"title":[{"title_sort":"Cell-free DNA and neuromediators in detecting aggressive variant prostate cancer","title":"Cell-free DNA and neuromediators in detecting aggressive variant prostate cancer"}],"relHost":[{"recId":"776629611","id":{"eki":["776629611"],"issn":["2296-5262"],"zdb":["2749752-5"]},"pubHistory":["37.2014 -"],"note":["Gesehen am 15.12.2023"],"origin":[{"publisherPlace":"Basel","dateIssuedKey":"2014","dateIssuedDisp":"2014-","publisher":"Karger"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"disp":"Cell-free DNA and neuromediators in detecting aggressive variant prostate cancerOncology research and treatment","type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"Oncology research and treatment","title":"Oncology research and treatment"}],"part":{"volume":"41","year":"2018","extent":"7","text":"41(2018), 10, Seite 627-633","pages":"627-633","issue":"10"}}],"name":{"displayForm":["Jost von Hardenberg, Thomas S. Worst, Niklas Westhoff, Philipp Erben, Stefan Fuxius, Markus Müller, Christian Bolenz, Christel Weiss, Elmar Heinrich"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1662892004","id":{"doi":["10.1159/000490618"],"eki":["1662892004"]}} | ||
| SRT | |a HARDENBERGCELLFREEDN1020 | ||